| 000 | 01653cam a2200181 4500500 | ||
|---|---|---|---|
| 005 | 20250112044352.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aLubin, Vanessa _eauthor |
| 700 | 1 | 0 |
_a Amar Hoffet, Aurélie _eauthor |
| 700 | 1 | 0 |
_a Dewailly, Didier _eauthor |
| 245 | 0 | 0 | _aPolycystic ovary syndrome: A metabolic time bomb |
| 260 | _c2023. | ||
| 500 | _a33 | ||
| 520 | _aPolycystic ovary syndrome (PCOS) is a huge public health issue, because of its high prevalence among the female population of reproductive age (over 10% worldwide), and because of its endocrine, reproductive, gynecological, obstetrical, dermatological, and psychological consequences. Although menstrual disorders and hyperandrogenemia may be the first-line complaint at a young age, long-term prognosis is impacted by cardiovascular risk factors related to insulin resistance. PCOS is chronic disease with metabolic implication: it triples the risk of type 2 diabetes and cardiovascular issues, and increases the risk of sleep apnea tenfold. As of 2023, the European Society of Human Reproduction and Embryology, American Society for Reproductive Medicine, Endocrine Society, and European Society of Endocrinology recommend a screening strategy for diabetes in those with PCOS. Tools for preventing these risks are also recommended, including lifestyle intervention, nutritional intervention, regular physical activity, and psychological support, as well as lifelong follow-up. | ||
| 786 | 0 | _nMédecine de la Reproduction | 25 | 3 | 2023-07-01 | p. 293-302 | 2650-8427 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-medecine-de-la-reproduction-2023-3-page-293?lang=en |
| 999 |
_c190491 _d190491 |
||